Thus, medications that were approved for the treatment of CKD by regulatory authorities shortly before or after 2010 and 2011 (such as sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide 1 receptor agonists) were either not available or not routinely used throughout the study periods. Here, GLP1R is linked to chronic kidney disease.